Economic issues for the UK biotechnology sector

New Genetics and Society

Volumn 21, Issue 2, 2002, Pages 109-130

  Van Reenen, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOTECHNOLOGY; DRUG INDUSTRY; ECONOMIC ASPECT; EUROPE; INDUSTRY; MARKET; PRIORITY JOURNAL; PUBLIC OPINION; SCIENCE; UNITED KINGDOM;

EID: 0036695459     PISSN: 14636778     EISSN: None     Source Type: Journal    
DOI: 10.1080/1463677022000006970     Document Type: Article

References (28)

1. Aghion, P. & Tirole, J. (1994) The management of innovation, Quarterly Journal of Economics, 109, pp. 1185-1209.
2. Arrow, K. (1962) Economic welfare and the allocation of resources for invention. In: Nelson, R. (ed.) The Rate and Direction of Inventive Activity (Princeton, NJ: Princeton University Press).
3. Bloom, N. & Van Reenen, J. (1998) Pharmaceutical regulation in the UK: where do we go from here?, Fiscal Studies, 19, pp. 347-74.
4. Bond, S., Harhoff, D. & Van Reenen, J. (1999) Investment, R&D and financial constraints in Britain and Germany, Institute for Fiscal Studies Working Paper 99/5 (www.ifs.org.UK/workingpapers/bhvr26.pdf).
5. Cap Gemini Ernst and Young (2001) The 15th Biotechnology Industry Annual Report (London: Cap Gemini Ernst and Young International).
6. Chennells, L., Dilnot, A. & Emerson, K. (2000) The IFS Green Budget (London: Institute for Fiscal Studies).
7. Cohen, W. & Levin, D. (1989) Empirical studies of innovative activity. In: Schmalensee, R. & Willig (eds) Handbook of Industrial Organisation (Amsterdam: Kluwer).
8. Dasgupta, P. & David, P. (1994) Towards a new economics of science, Research Policy, 23, pp. 487-521.
9. Department of Trade and Industry (1999) Biotechnology clusters, a report led by Lord Sainsbury (www.dti.gov.UK/biotechclusters/).
10. Economic and Social Research Council (1997) Uncertain World: Genetically Modified Organisms, Food and Public Attitudes in Britain (London: Global Environmental Change Programme).
11. Ernst and Young (1998a) European Life Sciences 98 - Continental Shift. The Fifth Annual Report on the European Life Sciences Industry (London: Ernst and Young International).
12. Ernst and Young (1998b) The 12th Biotechnology Industry Annual Report - New Direction 98 (London: Ernst and Young International).
13. Gambardella, A. (1995) Science and Innovation: The US Pharmaceutical Industry (Cambridge: Cambridge University Press).
14. Griffith, R., Redding, S. & Van Reenen, J. (2000) Mapping the two faces of R&D: productivity growth in a panel of OECD industries, CEPR Discussion Paper 2457 (www.ifs.org.UK/workingpapers/wp0002.pdf).
15. Griliches, Z. (1998) R&D and Productivity: The Econometric Evidence (Chicago, IL: Chicago University Press).
16. Henderson, R. & Cockburn, I. (1996) Scale, scope and spillovers: the determinants of research in drug productivity, Rand Journal of Economics, 27, pp. 32-57.
17. Herrara, S. (2001) Out of the lab, Red Herring.
18. Himmelberg, C. & Peterson, B. (1994) R&D and internal finance: a panel data study of small firms in high tech industries, Review of Economics and Statistics, 76, pp. 38-51.
19. Her Majesty's Treasury (1999) Pre Budget Report (London: HMSO).
20. Kortum, S. & Lerner, J. (2000) Assessing the contribution of venture capital to innovation, Rand Journal of Economics, 31, pp. 674-92.
21. Krugman, P. (1998) Peddling Prosperity (Cambridge, MA: MIT Press).
22. Lerner, J. & Tsai, A. (2000) Do equity financing cycles matter? Evidence from biotechnology alliances, National Bureau of Economic Research Working Paper 7464.
23. McKinsey Global Institute (1998) Productivity in the United Kingdom (London: McKinsey).
24. Porter, M. (1990) The Competitive Advantage of Nations (Cambridge, MA: Harvard University Press).
25. Sharp, M. & Patel, P. (1996) Europe's Pharmaceutical Industry: An Innovation Profile, draft prepared for DGXIII, April.
26. Simpson, H. (1998) Biotechnology and the Economics of Discovery in the Pharmaceutical Industry (London: Office of Health Economics).
27. Van Reenen, J. (1997) Why has Britain had slower R&D growth?, Research Policy, 26, pp. 493-507.
28. Zucker, L., Darby, M. & Brewer, B. (1997) Intellectual human capital and the birth of US biotechnology enterprises, American Economic Review, 87.